Review



osm  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    R&D Systems osm
    Osm, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 144 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+recombinant+oncostatin+m/Recombinant+Human+Oncostatin+M+(OSM)+Protein/pm41986711-647-160-164
    Average 95 stars, based on 144 article reviews
    osm - by Bioz Stars, 2026-10
    95/100 stars

    Images

    Related Articles

    Recombinant:

    Article Title: A genome-wide RNAi screen identifies MASK as a positive regulator of cytokine receptor stability
    Article Snippet: Reverse transfections with siRNA were carried out using Lipofectamine RNAiMAX (Invitrogen) using 10nM final concentrations of single siRNAs (Dharmacon), targeting ANKHD1 (D-014405-01 or D-014405-02) where comparable results in terms of knockdown efficiency and reduction in JAK/STAT pathway activity were seen for both, or non-targeting siRNA as a control, D-001210-01. .. Stimulation of mammalian JAK/STAT pathway was carried out using human recombinant oncostatin M, (295-OM-010, R&D systems) at a final concentration of 10ng/ml for 20 minutes. ..

    Article Title: Complete suspension culture of human induced pluripotent stem cells supplemented with suppressors of spontaneous differentiation
    Article Snippet: After 9–13 days, medium was changed every day to HDM with 20 ng/mL human recombinant HGF (R&D Systems). .. After 14–24 days, medium was changed every 2 days to Hepatocyte Culture Medium (Lonza) with 20 ng/mL human recombinant Oncostatin M (R&D Systems). .. On differentiation day 25, the albumin concentration in the culture supernatant was determined by ELISA using an anti-human albumin antibody (Betyl Laboratories, Cat#E88-129).

    Article Title: Expansion of OSMR expression and signaling in the human dorsal root ganglion links OSM to neuropathic pain
    Article Snippet: .. Human recombinant Oncostatin M (R&D Systems, Cat# 8475-OM or Sigma-Aldrich Cat# O9635) was preformulated and lyophilized in BSA to increase protein shelf-life. ..

    Article Title: Mesenchymal stem cells stimulate angiogenesis in a murine xenograft model of A549 human adenocarcinoma through an LPA1 receptor-dependent mechanism.
    Article Snippet: Abbreviations: CAFs, carcinoma-associated fibroblas actin; MSCs, mesenchymal stem cells; LPA, lysophos adipose tissue-derived mesenchymal stem cells; GAPDH dehydrogenase; DAPI, 4',6-diamidino-2-phenylindole; PCR, reverse polymerase-polymerase chain reaction; shRNA, short hairpin RNA; HUVECs, human umbilical enzyme-linked immunosorbent assay; TGF-β1, transfor vascular endothelial growth factor; SDF-1, stromal cell⁎ Corresponding author.. Department of Physiology, Sch University, Yangsan 626-770, Gyeongsangnam-do, Repub 8073; fax: +82 51 510 8076.. E-mail address: jhkimst@pusan.ac.kr (J.H.

    Article Title: Complete suspension culture of human induced pluripotent stem cells supplemented with suppressors of spontaneous differentiation
    Article Snippet: After 9 to 13 days, medium was changed every day to HDM with 20 ng/mL human recombinant HGF (R&D Systems). .. After 14 to 24 days, medium was changed every 2 days to Hepatocyte Culture Medium (HCM; Lonza) with 20 ng/mL human recombinant Oncostatin M (R&D Systems). .. On differentiation day 25, the albumin concentration in the culture supernatant was determined by ELISA using an anti-human albumin antibody (Betyl Laboratories, Catalog # E88-129).

    Article Title: A genome-wide RNAi screen identifies MASK as a positive regulator of cytokine receptor stability
    Article Snippet: Reverse transfections with siRNA were carried out using Lipofectamine RNAiMAX (Invitrogen) using 10 nM final concentrations of single siRNAs (Dharmacon), targeting ANKHD1 (D-014405-01 or D-014405-02) where comparable results in terms of knockdown efficiency and reduction in JAK/STAT pathway activity were seen for both, or non-targeting siRNA (D-001210-01) as a control. .. Stimulation of mammalian JAK/STAT pathway was carried out using human recombinant oncostatin M (295-OM-010, R&D systems) at a final concentration of 10 ng/ml for 20 min. Immunoprecipitation experiments were carried out as previously described ( Stec et al., 2013 ). .. Proteins were separated on 4–15% TGX SDS-PAGE precast gels (Bio-Rad) and transferred onto nitrocellulose membranes.

    Article Title: Oncostatin M-induced ABCC2 suppression sensitizes hepatocellular carcinoma cells to chemotherapeutics.
    Article Snippet: .. Human recombinant Oncostatin M (R&D System) was added for 3 days to all cell lines at a final concentration of 10 ng/cm3 prior any experiment. ..

    Concentration Assay:

    Article Title: A genome-wide RNAi screen identifies MASK as a positive regulator of cytokine receptor stability
    Article Snippet: Reverse transfections with siRNA were carried out using Lipofectamine RNAiMAX (Invitrogen) using 10nM final concentrations of single siRNAs (Dharmacon), targeting ANKHD1 (D-014405-01 or D-014405-02) where comparable results in terms of knockdown efficiency and reduction in JAK/STAT pathway activity were seen for both, or non-targeting siRNA as a control, D-001210-01. .. Stimulation of mammalian JAK/STAT pathway was carried out using human recombinant oncostatin M, (295-OM-010, R&D systems) at a final concentration of 10ng/ml for 20 minutes. ..

    Article Title: A genome-wide RNAi screen identifies MASK as a positive regulator of cytokine receptor stability
    Article Snippet: Reverse transfections with siRNA were carried out using Lipofectamine RNAiMAX (Invitrogen) using 10 nM final concentrations of single siRNAs (Dharmacon), targeting ANKHD1 (D-014405-01 or D-014405-02) where comparable results in terms of knockdown efficiency and reduction in JAK/STAT pathway activity were seen for both, or non-targeting siRNA (D-001210-01) as a control. .. Stimulation of mammalian JAK/STAT pathway was carried out using human recombinant oncostatin M (295-OM-010, R&D systems) at a final concentration of 10 ng/ml for 20 min. Immunoprecipitation experiments were carried out as previously described ( Stec et al., 2013 ). .. Proteins were separated on 4–15% TGX SDS-PAGE precast gels (Bio-Rad) and transferred onto nitrocellulose membranes.

    Article Title: Oncostatin M-induced ABCC2 suppression sensitizes hepatocellular carcinoma cells to chemotherapeutics.
    Article Snippet: .. Human recombinant Oncostatin M (R&D System) was added for 3 days to all cell lines at a final concentration of 10 ng/cm3 prior any experiment. ..

    other:

    Article Title: A genome-wide RNAi screen identifies MASK as a positive regulator of cytokine receptor stability
    Article Snippet: Quantitative real-time PCR Total RNA was extracted from cells using TRIZOL Reagent (Invitrogen) following the manufacturer's instructions.

    Immunoprecipitation:

    Article Title: A genome-wide RNAi screen identifies MASK as a positive regulator of cytokine receptor stability
    Article Snippet: Reverse transfections with siRNA were carried out using Lipofectamine RNAiMAX (Invitrogen) using 10 nM final concentrations of single siRNAs (Dharmacon), targeting ANKHD1 (D-014405-01 or D-014405-02) where comparable results in terms of knockdown efficiency and reduction in JAK/STAT pathway activity were seen for both, or non-targeting siRNA (D-001210-01) as a control. .. Stimulation of mammalian JAK/STAT pathway was carried out using human recombinant oncostatin M (295-OM-010, R&D systems) at a final concentration of 10 ng/ml for 20 min. Immunoprecipitation experiments were carried out as previously described ( Stec et al., 2013 ). .. Proteins were separated on 4–15% TGX SDS-PAGE precast gels (Bio-Rad) and transferred onto nitrocellulose membranes.



    Similar Products

    95
    R&D Systems osm
    Osm, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+recombinant+oncostatin+m/Recombinant+Human+Oncostatin+M+(OSM)+Protein/pm41986711-647-160-164
    Average 95 stars, based on 1 article reviews
    osm - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    94
    R&D Systems recombinant human oncostatin m
    Recombinant Human Oncostatin M, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+recombinant+oncostatin+m/Recombinant+Human+Oncostatin+M+(HEK-293-expressed)+Protein/pm41932341-856-40-46
    Average 94 stars, based on 1 article reviews
    recombinant human oncostatin m - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    95
    R&D Systems oncostatin m
    Oncostatin M, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+recombinant+oncostatin+m/Recombinant+Human+Oncostatin+M+(OSM)+Protein/pmc13130449-110-27-30
    Average 95 stars, based on 1 article reviews
    oncostatin m - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    94
    R&D Systems hosm
    (A-C) Proliferation assays of primary LSECs treated with increasing doses <t>of</t> <t>hLIF</t> (A), <t>hOSM</t> (B) or hCT-1 (C). 100 ng/mL hLIF was used as positive control. (D) Proliferation assays of LSECs isolated from lifrΔEC mice treated with increasing doses of hLIF. (E&F) Proliferation assays of LSECs isolated from lifr f/f (E) or lifrΔEC (F) mice treated with increasing doses of hVEGF. (G&H) Western blot analysis of primary LSECs treated with hVEGF (G) or hLIF (H) (I) Western blot of primary hepatocytes treated with hLIF. (J) Proliferation assays of primary hepatocytes treated with increasing doses of hLIF. (K) Proliferation assays of AML12 cells treated with increasing doses of hLIF. (L) Immunofluorescence staining of AML12 cells treated with 80 ng/mL hHGF or hLIF. DAPI (blue), Ki67 (green). Scale bar: 50 μm.
    Hosm, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+recombinant+oncostatin+m/Recombinant+Human+Oncostatin+M+(HEK-293-expressed)+Protein/bio_rxiv__64898__2026__02__24__707802-241-11-12
    Average 94 stars, based on 1 article reviews
    hosm - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    95
    R&D Systems human recombinant oncostatin m
    (A-C) Proliferation assays of primary LSECs treated with increasing doses <t>of</t> <t>hLIF</t> (A), <t>hOSM</t> (B) or hCT-1 (C). 100 ng/mL hLIF was used as positive control. (D) Proliferation assays of LSECs isolated from lifrΔEC mice treated with increasing doses of hLIF. (E&F) Proliferation assays of LSECs isolated from lifr f/f (E) or lifrΔEC (F) mice treated with increasing doses of hVEGF. (G&H) Western blot analysis of primary LSECs treated with hVEGF (G) or hLIF (H) (I) Western blot of primary hepatocytes treated with hLIF. (J) Proliferation assays of primary hepatocytes treated with increasing doses of hLIF. (K) Proliferation assays of AML12 cells treated with increasing doses of hLIF. (L) Immunofluorescence staining of AML12 cells treated with 80 ng/mL hHGF or hLIF. DAPI (blue), Ki67 (green). Scale bar: 50 μm.
    Human Recombinant Oncostatin M, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+recombinant+oncostatin+m/Recombinant+Human+Oncostatin+M+(OSM)+Protein/pm41724058-53-0-4
    Average 95 stars, based on 1 article reviews
    human recombinant oncostatin m - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    95
    R&D Systems maturation medium
    (A-C) Proliferation assays of primary LSECs treated with increasing doses <t>of</t> <t>hLIF</t> (A), <t>hOSM</t> (B) or hCT-1 (C). 100 ng/mL hLIF was used as positive control. (D) Proliferation assays of LSECs isolated from lifrΔEC mice treated with increasing doses of hLIF. (E&F) Proliferation assays of LSECs isolated from lifr f/f (E) or lifrΔEC (F) mice treated with increasing doses of hVEGF. (G&H) Western blot analysis of primary LSECs treated with hVEGF (G) or hLIF (H) (I) Western blot of primary hepatocytes treated with hLIF. (J) Proliferation assays of primary hepatocytes treated with increasing doses of hLIF. (K) Proliferation assays of AML12 cells treated with increasing doses of hLIF. (L) Immunofluorescence staining of AML12 cells treated with 80 ng/mL hHGF or hLIF. DAPI (blue), Ki67 (green). Scale bar: 50 μm.
    Maturation Medium, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+recombinant+oncostatin+m/Recombinant+Human+Oncostatin+M+(OSM)+Protein/pm41643903-324-22-37
    Average 95 stars, based on 1 article reviews
    maturation medium - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    95
    R&D Systems gm csf
    (A-C) Proliferation assays of primary LSECs treated with increasing doses <t>of</t> <t>hLIF</t> (A), <t>hOSM</t> (B) or hCT-1 (C). 100 ng/mL hLIF was used as positive control. (D) Proliferation assays of LSECs isolated from lifrΔEC mice treated with increasing doses of hLIF. (E&F) Proliferation assays of LSECs isolated from lifr f/f (E) or lifrΔEC (F) mice treated with increasing doses of hVEGF. (G&H) Western blot analysis of primary LSECs treated with hVEGF (G) or hLIF (H) (I) Western blot of primary hepatocytes treated with hLIF. (J) Proliferation assays of primary hepatocytes treated with increasing doses of hLIF. (K) Proliferation assays of AML12 cells treated with increasing doses of hLIF. (L) Immunofluorescence staining of AML12 cells treated with 80 ng/mL hHGF or hLIF. DAPI (blue), Ki67 (green). Scale bar: 50 μm.
    Gm Csf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+recombinant+oncostatin+m/Recombinant+Human+Oncostatin+M+(OSM)+Protein/pm41595754-56-46-52
    Average 95 stars, based on 1 article reviews
    gm csf - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    Image Search Results


    (A-C) Proliferation assays of primary LSECs treated with increasing doses of hLIF (A), hOSM (B) or hCT-1 (C). 100 ng/mL hLIF was used as positive control. (D) Proliferation assays of LSECs isolated from lifrΔEC mice treated with increasing doses of hLIF. (E&F) Proliferation assays of LSECs isolated from lifr f/f (E) or lifrΔEC (F) mice treated with increasing doses of hVEGF. (G&H) Western blot analysis of primary LSECs treated with hVEGF (G) or hLIF (H) (I) Western blot of primary hepatocytes treated with hLIF. (J) Proliferation assays of primary hepatocytes treated with increasing doses of hLIF. (K) Proliferation assays of AML12 cells treated with increasing doses of hLIF. (L) Immunofluorescence staining of AML12 cells treated with 80 ng/mL hHGF or hLIF. DAPI (blue), Ki67 (green). Scale bar: 50 μm.

    Journal: bioRxiv

    Article Title: The LIF-LIFR Axis Promotes Liver Regeneration via Modulation of Angiogenesis and HGF Release from LSECs

    doi: 10.64898/2026.02.24.707802

    Figure Lengend Snippet: (A-C) Proliferation assays of primary LSECs treated with increasing doses of hLIF (A), hOSM (B) or hCT-1 (C). 100 ng/mL hLIF was used as positive control. (D) Proliferation assays of LSECs isolated from lifrΔEC mice treated with increasing doses of hLIF. (E&F) Proliferation assays of LSECs isolated from lifr f/f (E) or lifrΔEC (F) mice treated with increasing doses of hVEGF. (G&H) Western blot analysis of primary LSECs treated with hVEGF (G) or hLIF (H) (I) Western blot of primary hepatocytes treated with hLIF. (J) Proliferation assays of primary hepatocytes treated with increasing doses of hLIF. (K) Proliferation assays of AML12 cells treated with increasing doses of hLIF. (L) Immunofluorescence staining of AML12 cells treated with 80 ng/mL hHGF or hLIF. DAPI (blue), Ki67 (green). Scale bar: 50 μm.

    Article Snippet: The proteins which included hLIF (Abcam, #ab287941), hVEGF (R&D system, #293-VE), hOSM (R&D system, #8475-OM), hCT1 (R&D system, 612-CD-010), IL-6 (PeproTech, 200-06), hHGF(R&D system, 294-HG), mHGF (R&D system, 2207-HG-025), EGF (R&D system, 236-EG), aLIF (UCSD), MAb mouse IgG2a isotype control (BioXcell,C1.18.4, #BE0085), anti-VEGF antibody B20-4.1.1 (Genentech) were added to cells at various concentrations, as indicated in the figures.

    Techniques: Positive Control, Isolation, Western Blot, Immunofluorescence, Staining

    (A) Volcano plot of differentially secreted proteins from primary LSECs treated with 40 ng/mL LIF versus control (n = 4). (B&C) qPCR of lifr (B) and hgf (C) levels in LSECs isolated from lifr f/f mice with indicated treatments. (D) HGF concentrations in conditioned medium from LSECs treated with hLIF at the indicated doses. (E) HGF concentrations in conditioned medium from LSECs treated with 40 ng/mL hLIF in the presence of the STAT3 inhibitor C188-9 at the indicated doses. (F) HGF concentrations in conditioned medium from LSECs isolated from lifr f/f or lifrΔEC mice treated with hLIF, hCT-1 or hOSM. (G) Western blot analysis of hepatocytes co-cultured with LSECs with or without 40 ng/mL LIF. Quantification is shown in Figure S4C. (H) Model depicting LIF action on LSECs to stimulate angiogenesis and HGF release, thereby supporting hepatocyte proliferation via paracrine regulation.

    Journal: bioRxiv

    Article Title: The LIF-LIFR Axis Promotes Liver Regeneration via Modulation of Angiogenesis and HGF Release from LSECs

    doi: 10.64898/2026.02.24.707802

    Figure Lengend Snippet: (A) Volcano plot of differentially secreted proteins from primary LSECs treated with 40 ng/mL LIF versus control (n = 4). (B&C) qPCR of lifr (B) and hgf (C) levels in LSECs isolated from lifr f/f mice with indicated treatments. (D) HGF concentrations in conditioned medium from LSECs treated with hLIF at the indicated doses. (E) HGF concentrations in conditioned medium from LSECs treated with 40 ng/mL hLIF in the presence of the STAT3 inhibitor C188-9 at the indicated doses. (F) HGF concentrations in conditioned medium from LSECs isolated from lifr f/f or lifrΔEC mice treated with hLIF, hCT-1 or hOSM. (G) Western blot analysis of hepatocytes co-cultured with LSECs with or without 40 ng/mL LIF. Quantification is shown in Figure S4C. (H) Model depicting LIF action on LSECs to stimulate angiogenesis and HGF release, thereby supporting hepatocyte proliferation via paracrine regulation.

    Article Snippet: The proteins which included hLIF (Abcam, #ab287941), hVEGF (R&D system, #293-VE), hOSM (R&D system, #8475-OM), hCT1 (R&D system, 612-CD-010), IL-6 (PeproTech, 200-06), hHGF(R&D system, 294-HG), mHGF (R&D system, 2207-HG-025), EGF (R&D system, 236-EG), aLIF (UCSD), MAb mouse IgG2a isotype control (BioXcell,C1.18.4, #BE0085), anti-VEGF antibody B20-4.1.1 (Genentech) were added to cells at various concentrations, as indicated in the figures.

    Techniques: Control, Isolation, Western Blot, Cell Culture